Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 22;59(7):1186.
doi: 10.3390/medicina59071186.

Role of Percutaneous Ablation in the Management of Intrahepatic Cholangiocarcinoma

Affiliations
Review

Role of Percutaneous Ablation in the Management of Intrahepatic Cholangiocarcinoma

Georgios Charalampopoulos et al. Medicina (Kaunas). .

Abstract

Cholangiocarcinoma (CCA) is an invasive cancer accounting for <1% of all cancers and 10-15% of primary liver cancers. Intrahepatic CCA (iCCA) is associated with poor survival rates and high post-surgical recurrence rates whilst most diagnosed patients are not surgical candidates. There is a growing literature suggesting percutaneous ablative techniques for the management of patients with iCCA measuring ≤3 cm with contraindications to surgery as well as for recurrent or residual tumors aiming to provide local cancer treatment and control. Most used ablative therapies for iCCA include radiofrequency and microwave ablation with irreversible electroporation, cryoablation and reversible electroporation (electrochemotherapy) being less commonly encountered techniques. Due to the infiltrative margins of the lesion, there is a need for larger safety margins and ablation zone; multi-apparatus ablation or other variations of the technique such as balloon-assisted approaches can be utilized aiming to increase size of the zone of necrosis. The present review paper focuses upon the current role of percutaneous ablative techniques for the therapeutic management of iCCA. The purpose of this review is to present the current minimally invasive ablative techniques in the treatment of iCCA, including local control and survival rates.

Keywords: ablation; cancer; intrahepatic cholangiocarcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A). A 64 y-o female patient with a post-surgical recurrent solitary mass of intrahepatic cholangiocarcinoma. CT axial scan with no IV injection of contrast medium at the beginning of ablation session illustrating the hypodense iCCA mass (white circle). (B). Coronal CT reconstruction illustrating two microwave antennas (black arrows) placed in the mass. (C). MRI 12 months post ablation (TI-weighted sequence with fat signal suppression post IV injection of Gadolinium illustrates the zone of necrosis (white arrows).
Figure 2
Figure 2
(A) A 59 y-o male patient with a post-surgical recurrent solitary mass of intrahepatic cholangiocarcinoma. Coronal CT reconstruction during ablation illustrates 6 IRE needles (black arrows) placed at the mass. (B) CT axial scan post IV injection of contrast medium (arterial phase) illustrates the zone of necrosis (white arrows) 3 months post ablation with no signs of remnant or recurrent tumor.

References

    1. Banales J.M., Marin J.J., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z. - DOI - PMC - PubMed
    1. Saha S.K., Zhu A.X., Fuchs C.S., Brooks G.A. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21:594–599. doi: 10.1634/theoncologist.2015-0446. - DOI - PMC - PubMed
    1. Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klümpen H.J., Malka D., Primrose J.N., Rimassa L., Stenzinger A., Valle J.W., et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2022;34:127–140. doi: 10.1016/j.annonc.2022.10.506. - DOI - PubMed
    1. Nakeeb A., Pitt H.A., Sohn T.A., Coleman J., Abrams R.A., Piantadosi S., Hruban R.H., Lillemoe K.D., Yeo C.J., Cameron J.L. Cholangiocarcinoma: A Spectrum of Intrahepatic, Perihilar, and Distal Tumors. Ann. Surg. 1996;224:463–475. doi: 10.1097/00000658-199610000-00005. - DOI - PMC - PubMed
    1. Yamasaki S. Intrahepatic cholangiocarcinoma: Macroscopic type and stage classification. J. Hepato-Biliary-Pancreat. Surg. 2003;10:288–291. doi: 10.1007/s00534-002-0732-8. - DOI - PubMed

MeSH terms